Calliditas Therapeutics reports positive Phase 2 trial results for setanaxib combined with pembrolizumab in head and neck squamous cell carcinoma patients.

Calliditas Therapeutics reports positive Phase 2 trial results for setanaxib, a NOX enzyme inhibitor, combined with pembrolizumab for head and neck squamous cell carcinoma patients. Progression-free survival and overall survival improved significantly, and tumor biology changes aligned with setanaxib's mechanism of action. The company plans further trials for primary biliary cholangitis (Q3 2024) and idiopathic pulmonary fibrosis (Q4 2024).